Article Details
Retrieved on: 2022-01-05 16:10:24
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca's PARP inhibitor Lynparza should not be made available routinely on the NHS n England and Wales as a treatment for prostate cancer, ...
Article found on: pharmaphorum.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here